Raphas Co. Ltd
Raphas Co., Ltd. manufactures and sells biodegradable microneedles in Korea. The company offers skin care, medical device, whitening care, and wrinkle care under the Acropass brand; and health food product under the FitKong brand. It also supplies double-layer microneedle manufacturing technology; and provides original development manufacturing, and contract development and manufacturing organiza… Read more
Raphas Co. Ltd (214260) - Total Liabilities
Latest total liabilities as of September 2025: ₩50.14 Billion KRW
Based on the latest financial reports, Raphas Co. Ltd (214260) has total liabilities worth ₩50.14 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Raphas Co. Ltd - Total Liabilities Trend (2017–2024)
This chart illustrates how Raphas Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Raphas Co. Ltd Competitors by Total Liabilities
The table below lists competitors of Raphas Co. Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Reeder Teknoloji Sanayi ve Ticaret Anonim Sirketi
IS:REEDR
|
Turkey | TL2.07 Billion |
|
Cayson Acquisition Corp
NASDAQ:CAPNU
|
USA | $2.80 Million |
|
Deoleo S.A
PINK:SOSCF
|
USA | $424.52 Million |
|
Neuronetics Inc
NASDAQ:STIM
|
USA | $114.11 Million |
|
Byuksan Corp
KO:007210
|
Korea | ₩324.08 Billion |
|
Woosu AMS Co.Ltd
KQ:066590
|
Korea | ₩195.82 Billion |
|
Jaiprakash Associates Limited
NSE:JPASSOCIAT
|
India | ₹385.53 Billion |
Liability Composition Analysis (2017–2024)
This chart breaks down Raphas Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.83 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.67 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.61 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Raphas Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Raphas Co. Ltd (2017–2024)
The table below shows the annual total liabilities of Raphas Co. Ltd from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩46.73 Billion | -31.37% |
| 2023-12-31 | ₩68.10 Billion | +23.51% |
| 2022-12-31 | ₩55.13 Billion | +21.21% |
| 2021-12-31 | ₩45.49 Billion | +190.71% |
| 2020-12-31 | ₩15.65 Billion | +3.95% |
| 2019-12-31 | ₩15.05 Billion | +4.67% |
| 2018-12-31 | ₩14.38 Billion | +29.90% |
| 2017-12-31 | ₩11.07 Billion | -- |